Relation of Low-Density Lipoprotein Cholesterol to Ischemic Stroke in Patients With Nonvalvular Atrial Fibrillation

Published:January 25, 2017DOI:
      Low-density lipoprotein cholesterol (LDL-C) has been demonstrated as an independent risk factor of ischemic stroke, but the association of LDL-C with ischemic stroke in patients with nonvalvular atrial fibrillation (AF) remains uncertain. Our objective was to explore whether LDL-C could refine stroke stratification in patients with AF. A total of 424 nonvalvular patients with AF with ischemic stroke and 391 ones without ischemic stroke were enrolled. No patient had received antithrombotic therapy. Multivariate logistic regression analysis showed that LDL-C was an independent predictor of ischemic stroke in patients with AF, with the adjusted odds ratio of 2.004 (95% confidence interval 1.624 to 2.473; p <0.001). The receiver operating characteristic analysis revealed that the best cut-off value of LDL-C to predict ischemic stroke in patients with AF was 2.48 mmol/L with 56.3% sensitivity and 66.3% specificity (area under the curve: 0.651, p <0.001). In the subgroup analysis based on different CHA2DS2-VASc scores, the predictive value of LDL-C remained significant in patients with a CHA2DS2-VASc score of ≤5. In conclusion, LDL-C was an independent predictor of ischemic stroke, which could potentially refine stroke stratification in patients with AF. A prospective study with a large number of patients is required to validate the current findings.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Camm A.J.
        • Lip G.Y.
        • De Caterina R.
        • Savelieva I.
        • Atar D.
        • Hohnloser S.H.
        • Hindricks G.
        • Kirchhof P.
        2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.
        Eur Heart J. 2012; 33: 2719-2747
        • Anandasundaram B.
        • Lane D.A.
        • Apostolakis S.
        • Lip G.Y.H.
        The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review.
        J Thromb Haemost. 2013; 11: 975-987
        • Bekwelem W.
        • Jensen P.N.
        • Norby F.L.
        • Soliman E.Z.
        • Agarwal S.K.
        • Lip G.Y.
        • Pan W.
        • Folsom A.R.
        • Longstreth W.J.
        • Alonso A.
        • Heckbert S.R.
        • Chen L.Y.
        Carotid atherosclerosis and stroke in atrial fibrillation: The Atherosclerosis Risk in Communities Study.
        Stroke. 2016; 47: 1643-1646
        • Berliner J.A.
        • Navab M.
        • Fogelman A.M.
        • Frank J.S.
        • Demer L.L.
        • Edwards P.A.
        • Watson A.D.
        • Lusis A.J.
        Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics.
        Circulation. 1995; 91: 2488-2496
        • Fulcher J.
        • O'Connell R.
        • Voysey M.
        • Emberson J.
        • Blackwell L.
        • Mihaylova B.
        • Simes J.
        • Collins R.
        • Kirby A.
        • Colhoun H.
        • Braunwald E.
        • La Rosa J.
        • Pedersen T.R.
        • Tonkin A.
        • Davis B.
        • Sleight P.
        • Franzosi M.G.
        • Baigent C.
        • Keech A.
        Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
        Lancet. 2015; 385: 1397-1405
        • Alperovitch A.
        • Kurth T.
        • Bertrand M.
        • Ancelin M.L.
        • Helmer C.
        • Debette S.
        • Tzourio C.
        Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study.
        BMJ. 2015; 350: h2335
        • De Caterina R.
        • Scarano M.
        • Marfisi R.
        • Lucisano G.
        • Palma F.
        • Tatasciore A.
        • Marchioli R.
        Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials.
        J Am Coll Cardiol. 2010; 55: 198-211
        • Potpara T.S.
        • Polovina M.M.
        • Licina M.M.
        • Marinkovic J.M.
        • Prostran M.S.
        • Lip G.Y.
        Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade Atrial Fibrillation Study.
        Circ Arrhythm Electrophysiol. 2012; 5: 319-326
        • Olesen J.B.
        • Torp-Pedersen C.
        • Hansen M.L.
        • Lip G.Y.
        The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
        Thromb Haemost. 2012; 107: 1172-1179
        • January C.T.
        • Wann L.S.
        • Alpert J.S.
        • Calkins H.
        • Cigarroa J.E.
        • Cleveland J.J.
        • Conti J.B.
        • Ellinor P.T.
        • Ezekowitz M.D.
        • Field M.E.
        • Murray K.T.
        • Sacco R.L.
        • Stevenson W.G.
        • Tchou P.J.
        • Tracy C.M.
        • Yancy C.W.
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
        J Am Coll Cardiol. 2014; 64: e1-e76
        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • Ahlsson A.
        • Atar D.
        • Casadei B.
        • Castella M.
        • Diener H.C.
        • Heidbuchel H.
        • Hendriks J.
        • Hindricks G.
        • Manolis A.S.
        • Oldgren J.
        • Popescu B.A.
        • Schotten U.
        • Van Putte B.
        • Vardas P.
        2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO).
        Eur Heart J. 2016; 37: 2893-2962
        • van den Ham H.A.
        • Klungel O.H.
        • Singer D.E.
        • Leufkens H.G.
        • van Staa T.P.
        Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation: results from a National Primary Care Database.
        J Am Coll Cardiol. 2015; 66: 1851-1859
        • Chen J.Y.
        • Zhang A.D.
        • Lu H.Y.
        • Guo J.
        • Wang F.F.
        • Li Z.C.
        CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis.
        J Geriatr Cardiol. 2013; 10: 258-266